Company managing a portfolio of royalties from respiratory assets partnered with global pharmaceutical companies.
Innoviva, Inc. is actively involved in the development and global commercialization of pharmaceuticals, with a focus on enhancing treatment options for patients both in the United States and internationally. Among its prominent products is RELVAR/BREO ELLIPTA, a once-daily medication that combines a long-acting beta2 agonist (LABA), vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate. Additionally, Innoviva offers ANORO ELLIPTA, another once-daily medication that merges a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, vilanterol (VI). Furthermore, TRELEGY ELLIPTA, also a once-daily combination medicine, features an ICS, LAMA, and LABA formulation.
Innoviva has strategically partnered with Sarissa Capital Management LP and maintains a collaboration agreement with Glaxo Group Limited. This collaboration is dedicated to the development and commercialization of advanced therapies for chronic obstructive pulmonary disease (COPD) and asthma using once-daily delivery systems. The company, originally known as Theravance, Inc., underwent a name change to Innoviva, Inc. in January 2016. Established in 1996 and headquartered in Burlingame, California, Innoviva continues to expand its portfolio and global footprint in the pharmaceutical industry.
Innoviva's commitment extends beyond product development; it emphasizes innovation and accessibility in healthcare solutions, addressing critical medical needs worldwide. Through its strategic alliances and ongoing research efforts, Innoviva aims to pioneer advancements that improve patient outcomes and quality of life. With a steadfast dedication to scientific excellence and partnership-driven growth strategies, Innoviva remains at the forefront of innovation in respiratory medicine, continually striving to redefine standards of care and meet the evolving needs of patients and healthcare providers alike.
Driven by a mission to deliver impactful therapies, Innoviva leverages its expertise and collaborative approach to create sustainable value for stakeholders while prioritizing patient-centric innovation. By harnessing cutting-edge technologies and strategic partnerships, Innoviva is poised to shape the future of respiratory healthcare, ensuring that its products make a meaningful difference in the lives of patients globally.